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Introduction 
Protein toxins  important tools in  
cell biology and medicine 
Protein toxins from bacteria and plants may cause life-threatening 
diseases and poisoning in humans. However, they are also prom-
ising as immunotoxins for targeted drug delivery, and they 
provide valuable information on trafficking pathways in cells 
important for elucidating molecular mechanisms behind disease.  
The family of AB toxins consists of toxins with an enzymatically 
active A-subunit and a surface-binding B-subunit. AB toxins 
produced by bacteria include Shiga toxin and Shiga-like toxins, 
cholera toxin, diphtheria toxin, anthrax toxin, and Pseudomonas 
exotoxin A (1-3). Shiga toxin is produced by the bacterium 
Shigella dysenteriae, which causes dysentery in humans. The 
closely related Shiga-like toxins made by Escherischia coli and 
some other bacterial strains are major causes of water- and food-
born infectious diseases world-wide, resulting in severe diarrhea 
and hemolytic uremic syndrome (HUS), which may cause renal 
failure in children. 
Some examples of AB toxins produced in plants are ricin, abrin, 
modeccin and viscumin (2,4). Ricin is found in the castor oil 
plant, Ricinus communis. The toxin is mainly present in the seeds 
and is purified from the aqueous phase, whereas the castor oil is 
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used as a laxative in medicine and as a lubricator for various 
industrial purposes.  
The toxic and transport properties of these toxins are exploited in 
the construction of immunotoxins, where antibodies that re-
cognize cancer cells are linked to the toxin for targeted therapy 
(5-7). Hormones or growth factors may also be used for re-
cognition of target cells. Clinical trials show promising results in 
cancer treatment for conjugates made from bacterial toxins, and a 
drug consisting of diphtheria toxin fused to a binding subunit for 
the interleukin-2 receptor has been approved for lymphoma treat-
ment (6-8). The non-toxic B-subunits of toxins may be used for 
delivery of therapeutic or diagnostic agents into cancer or 
immune cells (5). The Shiga toxin receptor Gb3 is overexpressed 
in certain cancers (5,9), and experiments are being performed 
with Shiga toxin B coupled to a drug against colon cancer (10).  
Shiga toxin B-conjugates targeting dendritic cells are also being 
investigated as vaccines against ovarian cancer (11). 
Several major breakthroughs in the studies of endocytosis and 
intracellular transport pathways have relied on protein toxins (12-
15). The toxins have thus proved to be valuable tools to increase 
the general knowledge of cell biology important for under-
standing and treatment of cancer as well as other diseases. 
Ricin and Shiga toxin  enzymes 
exploiting the endocytic pathway 
Belonging to the AB-family of toxins, ricin and Shiga toxin 
contain an enzymatically active A-moiety and a B-moiety 
responsible for binding to the cell surface. They follow the 
retrograde pathway to the endoplasmic reticulum (ER) before  
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Figure 1. Schematic and crystallographic structures of ricin and Shiga toxin with A- 
and B-subunits (PDB protein databank). A) Ricin (PDB: 2AA1). B) Shiga toxin 
(PDB: 1DMO). 
getting access to the cytosol and intoxicating cells (2-4,16). The 
A-subunit acts as a glycosidase, cleaving off an adenine from the 
28S RNA on the 60S ribosomal subunit. This prevents elongation 
factors from binding and inhibits protein synthesis. The A-
subunits are extremely efficient, and as little as one ricin molecule 
is sufficient to kill a cell (4). The size of the ricin A- and B-
subunits is about 30 kDa, and the A-chain is linked to the B-chain 
by a disulfide bridge which must be cleaved for enzymatic 
activity (figure 1A). Ricin binds to glycolipids and glycoproteins 
at the cell surface with a terminal galactose-residue creating 
millions of binding sites (2,4). 
Shiga toxin binds selectively to globotriaosylceramide (Gb3) on 
the cell surface, and does not bind to cells lacking this receptor 
(3). The Shiga toxin B-moiety consists of five B-chains of 7.5 
kDa each and is non-covalently linked to the A-subunit of 32 kDa 
(figure 1B). Before reaching the ER, the A-subunit is cleaved into 
 S 
S 
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two fragments, A1 and  A2, by the enzyme furin (17), and at least 
the enzymatically active A1-part must be translocated to the 
cytosol (3). 
The endocytic pathway and               
its key players 
Nutrients, growth factors, signaling molecules and other macro-
molecules in the extracellular matrix are taken up into cells by 
various types of endocytosis (18-21). Transport vesicles fuse with 
each other to form early endosomes, which constitute important 
sorting stations within the cell. The destiny of the vesicles is 
partly controlled by different surface markers dependent on origin 
and cargo. From the early endosomes cargo is recycled back to 
the plasma membrane, transported to lysosomes for degradation 
or delivered to the Golgi apparatus or the ER (figure 2). Newly 
synthesized proteins, lipids and carbohydrates follow the opposite 
trafficking pattern, the biosynthetic-secretory pathway, and there 
is a continuous, large-scale flow of transport vesicles in both 
directions. 
Rab GTPases, phosphoinositides (PIs) and coat proteins such as 
clathrin and sorting nexins (SNXs) are all key components in 
intracellular trafficking which have been studied in this thesis. 
The different Rabs and PIs are specific for certain organelles and 
thus maintain the compartmentalization of the cell (22-24). PIs 
recruit proteins that promote vesicular traffic to membranes, 
where some of the proteins form complexes such as clathrin 
coats, COP coats or SNX complexes (22,25,26). Rab GTPases 
can regulate PI metabolism by affecting downstream kinases. 
Furthermore, they interact with tethering factors and mediate 
docking of transport vesicles to the correct membrane (27-30). 
The SNARE proteins constitute another group of key factors in 
vesicle traffic. V-SNAREs pack with different cargo on the coat 
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of a budding vesicle, and bind to the complementary t-SNAREs 
on the target membrane to mediate fusion (25,31). Motor proteins 
such as dynein and kinesin connect vesicles to the actin filaments 
and microtubules of the cytoskeleton and promote transport 
between compartments (32).  
Rab GTPases 
Rab GTPases are molecular switches cycling between a cytosolic, 
inactive GDP-bound form and an active, membrane-attached 
GTP-bound form (22,28-31). Guanine nucleotide exchange 
factors (GEFs) replace GDP by GTP whereas GTPase-activating 
proteins (GAPs) catalyze the reverse reaction. Rab GTPases 
regulate cargo sorting, budding, transport, tethering, and fusion of 
transport vesicles. In the cytosol they form a complex with a 
GDP-dissociation inhibitor (GDI) which prevents insertion into 
membranes. GDI displacement factors (GDF)s are proposed to 
dissociate GDIs from Rabs at certain membrane surfaces, 
allowing nucleotide exchange and subsequent binding of effector 
proteins to the now active form (28).  
More than 60 human Rabs have been identified, and their cellular 
distribution is compartment specific (27). Rab4 and Rab5 are 
associated with different subdomains of early endosomes (33), 
and Rab5 has been shown to mediate early endosomal fusion 
(34). Rab7 is thought to replace Rab5 as the early endosomes 
mature into late endosomes (35), whereas Rab9 is a late endo-
somal marker found to meditate transport from late endosomes to 
the TGN (36-38). Rab11 is associated with early/recycling endo-
somes and the Golgi (39-41), and yet another Rab, Rab1, is 
mainly localized to the ER and controls vesicular traffic between 
the ER and the Golgi apparatus (42-44).  
The two Golgi-localized Rab6 isoforms Rab6A and Rab6A’ are 
created by alternative splicing of a duplicated exon and differ in 
only three amino acids near the GTP-binding domain (45). They 
bind GTP to similar extents and are ubiquitously expressed at 
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similar levels, whereas the third Rab6 isoform, Rab6B, is only 
expressed in a subset of neurons (45,46).  
Phospholipids 
PIs as well as Rab proteins are important markers of organelle 
identity. They serve as recruitment sites for coat proteins, motor 
proteins, tethering factors etc., thereby forming  membrane sub-
domains and regulating signaling and transport events in space 
and time (22,24,47). Their metabolism is controlled by organelle-
specific kinases and phosphatases. PI(4,5)P2 is abundant at the 
plasma membrane and interacts with proteins important for 
endocytosis; together with PI(4)P and PI(3)P it is also present at 
the Golgi apparatus (24,48). PI(3)P is most abundant on early 
endosomes, internal vesicles of multivesicular bodies, and in 
yeast vacuoles (49). 
Many proteins important for transport are peripheral-membrane 
proteins that possess specific PI-binding modules such as the 
FYVE, PHOX homology (PX), pleckstrin homology (PH), 
ENTH, and ANTH domains (23). PI(3)P is recognized by FYVE 
domains in proteins like EEA1, which regulate endosomal fusion, 
and by the PX domains of SNXs (50). PI(3)P can be generated 
either by a PI3-kinase phosphorylating PI or a phosphatase 
converting PI(3,5)P2 or PI(3,4,5)P3 into PI(3)P (51). The class III 
PI3-kinase Vps34 is conserved from yeast to mammals and has 
phosphatidylinositol as its only substrate. Being localized to early 
endosomes and forming different sub-complexes with other 
kinases, Vps34 has been shown to create PI(3)P for the auto-
phagic pathway, for the formation of multivesicular bodies and 
transport to late endosomes, as well as endosome-to-Golgi 
trafficking (52-55).  
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Sorting nexins 
So far 33 mammalian sorting nexins (SNXs) and 10 yeast SNXs 
have been identified (26,56). Members of the SNX protein family 
are recruited to membranes by their phosphoinositide-binding PX 
domain. Several SNXs, including SNX1, SNX2, and SNX4 
possess a BAR domain, which binds to curved membranes and in 
some cases induces membrane curvature (57). SNXs bind 
preferably to PI(3)P but can also bind to other PIs with different 
affinities and thereby localize to specific compartments in the 
early endocytic pathway. Many SNXs are conserved, and the 
retromer protein sorting complex on early endosomes was first 
identified in yeast (58). In mammals the retromer consists of a 
cargo binding sub-complex containing hVps26, hVps29 and 
hVps35 and a sub-complex thought to mediate membrane 
interactions consisting of SNX1 and SNX2. SNX5 and SNX6 
have also been suggested as retromer components (59). SNX4 
regulates a retromer-independent pathway to the Golgi in yeast 
(60) as well as recycling of transferrin (Tf) in human cells (61). 
SNX9 is involved in the activation of dynamin and N-WASP 
regulating endocytosis (62-64).  
Retrograde transport of ricin           
and Shiga toxin 
When endocytosed, ricin and Shiga toxin both follow the 
retrograde transport pathway from early endosomes through the 
Golgi apparatus before they enter the ER and are translocated to 
the cytosol (figure 2) (2-4,16). Notably, Shiga toxin was the first 
lipid-binding ligand found to be endocytosed by coated pits (14) 
and the first compound shown to exploit the retrograde pathway 
for trafficking all the way to the ER (15). In that way, the toxin 
may escape lysosomal degradation on its way to the cytosol. The  
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Figure 2. Intracellular transport routes in the endocytic pathway followed by 
different proteins. Ricin and Shiga toxin follow the retrograde pathway from early 
endosomes via the Golgi apparatus to the ER. Transport of Shiga toxin as well as 
recycling of TGN46 to the TGN is dependent on Rab11, which is associated with 
recycling endosomes. EGFR is transported via early and late endosomes to 
lysosomes, whereas TfR is recycled back to the plasma membrane. M6PR and furin 
are retrieved to the TGN from late endosomes via a Rab9-dependent route; 
however, M6PR can also be retrieved from earlier compartments. 
toxins may also be recycled back to the plasma membrane from 
early endosomes or transported to lysosomes for degradation. In 
fact, only 5 % of internalized ricin enters the retrograde pathway 
(65).  
Endocytosis  
Both ricin and Shiga toxin are endocytosed by clathrin-dependent 
as well as clathrin-independent mechanisms (2,3,21). Different  
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Figure 3. Endocytic mechanisms 
types of endocytosis are summarized in figure 3. The endocytic 
pathways differ in regards to the size of the vesicle, the type and 
destination of cargo, and the mechanisms of vesicle formation. 
The two main categories of endocytosis are phagocytosis (cell-
eating), the uptake of large particles such as bacteria into 
specialized cells, and pinocytosis (cell-drinking), the uptake of 
fluids and solutes which occur in all cell types (66). Macro-
pinocytic membrane protrusions are induced by signaling through 
Rho-GTPases and actin remodeling. They fuse with the plasma 
membrane and form endocytic vesicles greater than 1μm in 
diameter (66).  
Caveolae are membrane invaginations ~60 nm in size that are 
defined by the presence of the protein caveolin. They form on 
microdomains rich in cholesterol and sphingolipids, and 
dynamin-mediated remodeling of the actin cytoskeleton seems to 
be important for invagination. (18,21)  
Several endocytic processes require neither clathrin nor caveolin 
and may be divided into groups based on their requirements for 
dynamin, Cdc42, RhoA, or ARF6 (18,21,67). 
Clathrin-mediated internalization, where coated pits of ~120 nm 
in diameter pinch off to fuse with early endosomes, is the type of 
endocytosis best characterized (19,20,66,68,69). In the classical 
Arf6 
Clathrin- and caveolin-independent 
endocytosis 
Macropinocytosis Clathrin-
dependent 
endocytosis 
Caveolae 
RhoA Cdc42 
Dynamin 
Clathrin Caveolin 
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view of clathrin-mediated endocytosis ligand-induced uptake of 
receptors upon cargo-binding, such as growth factors or G-
protein-coupled receptors, can be distinguished from  constitutive 
endocytosis of non-signaling receptors like LDL receptor and 
transferrin receptor (TfR) occurring independently of ligand 
binding. So far four main types of internalization signals, which 
are recognized by adaptor or accessory proteins, have been 
described in transmembrane proteins. An increasing number of 
accessory proteins have been identified, some of them being 
specific for certain types of cargo. Thus, the existence of cargo-
specific clathrin-coated pits (CCPs) has been discussed (19).  
Displaying by far the largest number of interactions with other 
proteins, clathrin and AP-2 may be considered as hubs in the 
network of clathrin-coated vesicle (CCV) formation (68). The 
AP-2 complex, consisting of , 2, μ2 and 2 subunits, binds 
PI(4,5)P2 and cargo receptors and links cargo into the forming 
CCP. Accessory proteins such as AP180/CALM and epsin recruit 
clathrin and promote membrane curving. Clathrin triskelions form 
polygonal networks thought to stabilize the coated vesicle (70). 
Dynamin is recruited by the accessory proteins amphiphysin, 
SNX9 and/or intersectin and hydrolyses GTP for scission of the 
CCV. The actin cytoskeleton is also important in the scission. 
Auxilin and HSC70 ATP-ase are involved in un-coating of the 
CCV, leaving clathrin and AP-2 accessible for the formation of 
new CCPs (68,71). 
Signaling and endocytosis 
Several studies have revealed that signaling and endocytic events 
are mechanistically integrated in clathrin- as well as clathrin-
independent internalization (72,73). Binding of epidermal growth 
factor (EGF) and neuronal growth factor (NGF) to their tyrosine 
kinase receptors is known to induce auto-phosphorylation and 
subsequent signal transduction promoting clathrin-mediated 
endocytosis and degradation of the receptors. Moreover, the 
  11
induced activation of Src-kinases seems to affect clathrin phos-
phorylation and recruitment (74-76). Also endocytosis of the Fc 
receptors in macrophages and the B and T cell antigen receptors 
involve activation of Syk and Src kinases; in the case of BCR and 
TCR the activation is followed by clathrin phosphorylation (77-
79).  
Although binding to a glycolipid, Shiga toxin can induce 
apoptotic cascades as well as more rapid signaling in cells. Shiga 
toxin binding has been shown to activate the Src-kinases Yes and 
Lyn (80,81), the MAP-kinase p38 (82), the serine/threonine 
kinase PKC (83), and the tyrosine kinase Syk (84,85), as well as 
increasing microtubule formation (86,87). Syk-mediated phos-
phorylation of clathrin heavy chain seems to be important for 
uptake of Shiga toxin (84). Shiga toxin can promote its own 
recruitment to CCPs and induce its own uptake (14,88). Whereas 
Shiga toxin B seems to be sufficient for activating signaling 
cascades, the A-subunit increases the clathrin-dependent endo-
cytosis of the toxin (88). Shiga toxin B has also been reported to 
induce reorganization of membrane lipids causing tubular 
invaginations of the plasma membrane independent of CCPs (89). 
Endosome-to-Golgi transport 
Retrograde transport from endosomes to the Golgi apparatus has 
not been as well characterized as endocytic mechanisms and the 
lysosomal pathway. However, an increasing number of coat 
proteins, lipids, and recruitment, sorting, tethering and fusion 
factors in endosome-to-Golgi trafficking have now been identi-
fied, see figure 4 (90,91). Endogenous proteins utilizing this 
pathway include acid hydrolase sorting receptors like the 
mammalian mannose-6-phosphate receptors (MPRs) and the 
yeast Vps10p (90,91). These receptors deliver acid hydrolase 
precursors destined for lysosomes to early endosomes, and are 
recycled back to the TGN from early or late endosomes. 
Multiligand receptors such as sortilin and SorLa (92,93), the  
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Figure 4. Proteins associated with endosome-to-Golgi transport of Shiga toxin 
(black color) and ricin (blue color). Proteins thought to be involved in budding of 
vesicles are shown around early endosomes, whereas proteins thought to mediate 
tethering or fusion are shown near the Golgi apparatus. The sites of action of PKC 
and p38 are not known. Coat proteins and their adaptors contribute to vesicle 
formation at early endosomes. Rab proteins mediate correct docking and interact 
with tethering factors (Golgins and GARP/COG-complexes) at the TGN, whereas 
SNARE complexes mediate fusion.  
Golgi resident proteins TGN38/46, the SNARE membrane fusion 
proteins, and transmembrane enzymes/peptidases also cycle be-
tween endosomes and the TGN (90,91). Furthermore, the protein 
toxins ricin, Shiga toxin and cholera toxin take advantage of this 
pathway to reach the ER. There is evidence for more than one 
trafficking pathway between early endosomes and the TGN, and 
cargo may be transported from early, recycling or late endo-
somes. CI-MPR is retrieved from late endosomes to the TGN in a 
Rab9-dependent manner (36); however, CI-MPR can also be 
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retrieved from earlier compartments (94-96). The precursor 
protein-cleaving enzyme furin is also transported via late endo-
somes to the TGN (38). In contrast, Shiga toxin and ricin seem to 
bypass late endosomes on their way to the TGN and traffic 
independently of Rab9 (97,98).  
Four different kinases have been reported to play a role in endo-
some-to-Golgi transport of toxins. The serine/threonine kinase 
PKC and the MAP kinase p38 are activated by Shiga toxin and 
important for efficient transport to the TGN (82,83), and -
arrestins seem to serve as negative regulators of the p38 
dependent pathway (99). Protein kinase A type II was found to 
regulate endosome-to-Golgi transport of ricin (100), and hVps34 
is responsible for a specific pool of PI(3)P required for efficient 
transport of both Shiga toxin and ricin to the TGN (papers II and 
III).  
Lipids other than PIs are also crucial for efficient endosome-to-
Golgi trafficking of toxins. Cholesterol is required for targeting of 
ricin (101) as well as Shiga toxin (102) to the TGN. The lipid 
composition of the Gb3 receptor is also important for transport of 
Shiga toxin to the TGN and further to the ER (103-105). 
Coat proteins and adaptors necessary for Shiga toxin transport 
include clathrin and its binding partner epsinR, as well as 
dynamin (106,107) and the clathrin-associated PI(4,5)P2 phos-
phatase OCRL1 (108). Dynamin, but not clathrin, is also required 
for efficient transport of ricin (98,109). The retromer complex 
constitutes a coat different from clathrin, and its components 
hVps26, SNX1 and SNX2 have been shown to mediate 
endosome-to-Golgi transport of Shiga toxin (110,111) (paper III). 
SNX2 and SNX4, but not SNX1, are essential for transport of 
ricin to the TGN (paper II). Furthermore, EHD3 (eps15 homology 
domain-containing protein 3) and one of its interaction partners, 
the Rab4/5 effector rabenosyn-5, are necessary for SNX1 and 
SNX2 localization and thereby Shiga toxin transport from early 
endosomes to the Golgi (112).  
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The two isoforms of the small GTPase Rab6, Rab6A and Rab6A’, 
are both involved in ricin transport (paper I), whereas only 
Rab6A’ so far has been shown to function in transport of Shiga 
toxin to the TGN, along with two Rab6 effectors, the RabGAP 
Rab6IP2, and the Rab6-binding TATA element modulatory factor 
(TMF) (113-116). Rab11, being localized to early/recycling endo-
somes, is necessary for efficient transport of Shiga toxin, but not 
ricin (98,117). The Golgi-localized Rab43 and its RabGAP RN-
tre also seem to be needed for transport of Shiga toxin to the TGN 
and for maintaining Golgi morphology (118). Other RabGAPs 
identified as regulators of Shiga toxin transport are EV15, 
TBC1D10A, TBC1D10B, TBC1D10C and TBC1D17; however, 
possible effects on endocytosis have not been tested and their 
target Rabs remain unknown (118). 
Tethering factors involved in Shiga toxin transport include the 
small GTPase Arl1 and its effector golgin-97 (119,120), golgin-
245 (121), GCC185 (122), the COG (conserved oligomeric 
Golgi) complex (123), and the GARP (Golgi-associated 
retrograde protein) complex (124). Fusion of both Shiga toxin- 
and ricin-containing vesicles to the TGN is mediated by the 
SNARE complexes syntaxin5/Ykt6/GS15/GS28 and syntaxin6/ 
syntaxin16/Vti1a/VAMP3/4 (113,125,126). The cycling cis-Golgi 
trans-membrane protein GPP130 (Golgi phosphoprotein 130) is 
also involved in endosome-to-Golgi trafficking of Shiga toxin, 
but its exact function remains unknown (127,128). 
Furthermore, Shiga toxin increases the assembly of microtubules 
in cells (86), and both microtubules and the motor protein dynein 
are required for transport of this toxin (87). 
Golgi-to-ER transport and translocation to the cytosol 
ER-resident proteins contain a specific sequence that is recog-
nized by the KDEL-receptor, and they are recycled back to the 
ER from the Golgi by a mechanism dependent on coatomer 
protein I (COPI). Possessing a KDEL-like sequence, Pseudo-
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monas exotoxin A exploits this pathway to reach the ER (129). 
Ricin and Shiga toxin are transported to the ER despite their lack 
of a KDEL sequence (15,130), and they have both been shown to 
traffic independently of COPI (131-133). Shiga toxin follows a 
Rab6-regulated pathway that is also used by Golgi glycosylation 
enzymes (114,131,134,135). Furthermore, Cdc42, microtubule 
and actin have been described as regulators of Shiga toxin 
transport to the ER (136-138), with the movement on actin 
filaments being mediated by myosin motors (139).  
The ER chaperone protein disulfide isomerase (PDI) cleaves the 
disulfide bridge between ricin A and B-chain before the A-chain 
is translocated to the cytosol (140). This mechanism was 
previously described for dissociation of the A- and B-subunits of 
cholera toxin (141) and Pseudomonas exotoxin A (142). 
For translocation the toxin A-chains are thought to exploit the 
ERAD quality control pathway for misfolded proteins. However, 
they escape ubiquitin-mediated proteosomal degradation presu-
mably due to their low lysine content as shown for ricin (143). 
Ricin has been reported to interact with EDEM, a protein 
involved in retrotranslocation (144), as well as to translocate 
through the Sec61-channel (145). Also Shiga toxin, cholera toxin 
and Pseudomonas exotoxin A have been shown to associate with 
the Sec61-complex (146-149). Moreover, Shiga toxin interacts 
with the ER chaperone BiP (150). 
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Aims of the study 
The main objective of this project has been to identify new 
components in the retrograde trafficking of ricin and Shiga toxin, 
preferably in endosome-to-Golgi transport, and to study further 
details of the clathrin-dependent entry mechanism of Shiga toxin. 
Studies of toxin transport are helpful in revealing new players of 
these pathways, and the specific aims of the project were as 
follows: 
 To investigate the role of the Rab6 GTPase splice variants 
Rab6A and Rab6A’ in endosome-to-Golgi transport of ricin. 
 To study whether the PI3-kinase hVps34 regulate toxin 
transport. 
 To investigate if members of the sorting nexin protein family, 
namely SNX1, SNX2 and SNX4, are important for 
endosome-to-Golgi trafficking of Shiga toxin and ricin, and if 
the SNXs’ requirement for membrane lipids may be sustained 
by hVps34.  
 To study whether Shiga toxin, being able to stimulate its own 
uptake, is capable of increasing the formation of CCPs at the 
plasma membrane, and whether the observed increase is 
mediated by the kinase Syk.  
  17
Summary of publications 
Paper I. Transport of ricin from endosomes to the Golgi 
apparatus is regulated by Rab6A and Rab6A'. 
When we initiated our study, the splice variants of the Golgi-
localized small GTPase Rab6 had been proposed to take part in 
different steps of retrograde trafficking. Rab6A’ had been shown 
to mediate endosome-to-Golgi transport of Shiga toxin (113), 
whereas Rab6A had been suggested as a mediator of Shiga toxin 
transport from Golgi to ER (131,135). We specifically depleted 
each isoform by siRNA to determine if Rab6A and/or Rab6A’ 
played any role in endosome-to-Golgi transport of ricin. Trans-
port of ricin to the TGN was inhibited upon Rab6A knockdown 
when mRNA levels were reduced by more than 40 % but less 
than 75 %. When Rab6A mRNA levels were reduced by more 
than 75 %, Rab6A’ mRNA was up-regulated, and inhibition of 
ricin transport was no longer observed. This suggests that Rab6A’ 
is able to compensate for the loss of Rab6A. Furthermore, an 
almost complete knockdown of Rab6A’ inhibited ricin transport 
by ~40 %. However, in experiments where Rab6A at the same 
time was up-regulated, the inhibition of ~40 % was still observed. 
Combined knockdown of Rab6A and Rab6A’ reduced transport 
to the TGN by ~70 %.  
Less co-localization between ricin and TGN46 was observed by 
immunofluorescence microscopy when Rab6A was knocked 
down without any up-regulation of Rab6A’, and ricin seemed to 
localize further away from the nucleus than in control cells. 
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Similar results were obtained upon combined Rab6A/A’ 
knockdown. We concluded that both Rab6 isoforms are important 
in transport of ricin to the TGN and that they have some 
functional redundancy. Yet, only Rab6A’ is able to fully 
compensate for loss of the other isoform. This may indicate that 
the two isoforms control parallel transport pathways between 
early endosomes and the TGN.  
Paper II. Phosphoinositide-regulated retrograde transport of 
ricin: Crosstalk between hVps34 and sorting nexins. 
Phosphoinositides are important regulators of membrane traffic 
whose formation is specifically regulated by kinases and 
phosphatases. The main supplier of PI(3)P on early endosomes is 
the PI3-kinase Vps34 (151), which in yeast has been shown to 
regulate endosome-to-Golgi transport via the retromer complex 
(53). We therefore investigated if hVps34 was involved in endo-
some-to-Golgi transport of ricin and if any effectors of hVps34 in 
this pathway might be identified. Perturbation of hVps34 activity 
by the use of PI3-kinase inhibitors, overexpression of a dominant 
negative mutant, and siRNA led to reduced endosome-to-Golgi 
transport in HEK 293 cells, thus confirming the importance of 
this kinase. Moreover, ricin was localized to Rab7-positive 
endosomes when hVps34 activity was altered. 
We considered the mammalian orthologs of the yeast retromer 
component Vps5p, SNX1 and SNX2, as potential effector 
proteins for hVps34 in ricin transport. SNX4, a different PI(3)P- 
binding SNX, had been shown to mediate a retromer-independent 
retrieval pathway to the Golgi in yeast (60). We therefore used 
siRNA to knock down SNX1, SNX2, and SNX4 and measured 
endosome-to-Golgi transport of the toxin. Knockdown of SNX2 
or SNX4 reduced ricin transport to the TGN by ~40 %, similar to 
the effect observed by hVps34 siRNA, whereas a combined 
knockdown of SNX2 and SNX4 led to as much as 70 % 
reduction. Furthermore, transport of ricin to the TGN was able to 
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proceed as normal even in the absence of SNX1. These results 
identify SNX2 and SNX4 as effectors in hVps34-dependent 
transport, and may suggest that SNX2 and SNX4 operate in 
parallel and retromer-independent pathways between endosomes 
and the TGN. 
Paper III. SNX1 and SNX2 mediate retrograde transport      
of Shiga toxin. 
The retromer protein sorting complex on early endosomes has 
previously been shown to mediate retrieval of the CI-MPR from 
endosomes to the TGN (95,96). SNX1 and SNX2 have been 
identified as mammalian orthologs of the yeast retromer 
component Vps5p (152,153). Thus, we considered them as 
candidates for mediating endosome-to-Golgi trafficking of Shiga 
toxin as well as ricin. We used siRNA to specifically deplete 
Vero cells of SNX1 and SNX2 separately or in combination, and 
we obtained at least 80 % knockdown in all experiments. After 
knockdown of SNX1 or SNX2 alone, transport from endosomes 
to the TGN was reduced by  40 %, whereas a combined 
knockdown gave an ~80 % reduction. The endocytosis of Shiga 
toxin was not affected upon knockdown of neither SNX. 
Treatment of the cells with the PI3-kinase inhibitor wortmannin 
reduced the transport of Shiga toxin to the TGN by 50-75 % in a 
dose-dependent manner. We observed a similar response after 
knockdown of hVps34 by siRNA, suggesting that hVps34 is 
responsible for a pool of PI(3)P important for Shiga toxin 
transport in the same way as for ricin. Our results demonstrate 
that SNX1 and SNX2 are both important for endosome-to-Golgi 
transport of Shiga toxin and that they are only partly redundant.  
Paper IV. Shiga toxin increases formation of clathrin      
coated pits through Syk kinase. 
Clathrin-mediated endocytosis is an important entry mechanism 
for Shiga toxin (14). Several reports show that binding of Shiga 
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toxin to the Gb3-receptor induces signaling cascades in cells 
(80,81,86). Our lab has previously shown, that among other 
proteins, the tyrosine kinase Syk is activated and found to be 
important for the endocytosis of Shiga toxin (84). Shiga toxin-
mediated activation of Syk leads to phosphorylation of CHC and 
promotes the formation of a complex between Syk and clathrin. 
Bearing this in mind, we wished to study if Shiga toxin might 
have any effect on clathrin recruitment. Previous reports have 
suggested that binding of ligands such as EGF and NGF to their 
tyrosine kinase receptors may increase the recruitment of clathrin 
to the plasma membrane (74-76). We studied the amount and 
dynamics of CCPs before and after incubation with Shiga toxin/ 
Shiga toxin B by means of EM and live-cell confocal imaging. 
EM revealed that there was a 30-40 % increase in CCPs of HeLa 
and HEp-2 cells upon incubation with Shiga toxin. The increase 
was reproduced for Shiga toxin B by spinning disk confocal 
microscopy in HeLa cells stably expressing the AP-2 subunit 2 
coupled to EGFP. The new CCPs were internalized in the same 
way as normal CCPs. Interestingly, lifetime and maximum 
intensity distributions were shifted towards higher values. We 
also studied the uptake of Tf after addition of Shiga toxin B to the 
cells at various time points ranging from 2 to 15 min; however, 
there was no effect on Tf uptake. When inhibiting Syk with 
piceatannol, an increase in the formation of CCPs was no longer 
observed, indicating that Syk is important for this process. We 
propose that Shiga toxin, when binding to Gb3, induces activation 
of Syk and formation of a complex between Syk and CHC, and 
subsequently increases the formation of functional clathrin coats.  
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Discussion 
Rab GTPases, phosphoinositides and hetero-oligomeric protein 
complexes are crucial elements in intracellular trafficking. In the 
following I will discuss the importance of several such com-
ponents in transport of ricin and Shiga toxin to the Golgi as well 
as the effect of Shiga toxin on the clathrin coated pit machinery 
that we established during this study.  
Shiga toxin and the formation           
of clathrin-coated pits 
Shiga toxin has been shown to play an active part in its uptake 
and retrograde transport in cells. Our lab has previously 
demonstrated that Syk, being activated by Shiga toxin, phos-
phorylates clathrin and is important for Shiga toxin endocytosis 
(84,85). In connection with this, we show in paper IV that Shiga 
toxin and Shiga toxin B increase the formation of CCPs at the 
plasma membrane in a Syk-dependent manner. 
Signaling induced by ligand-binding to tyrosine kinase receptors 
has previously been found to stimulate the recruitment of CCPs. 
NGF increases the formation of CCPs and induces its clathrin-
dependent uptake by signaling through the receptor tyrosine 
kinase TrkA (75). Similarly, EGF activates its receptor and 
induces Src-dependent phosphorylation of CHC and redistri-
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bution of clathrin as well as recruitment of CCPs (74,76). The B-
cell antigen receptor BCR has no kinase activity, but in spite of 
this has been shown to induce Src-dependent phosphorylation of 
CHC important for clathrin-mediated endocytosis of BCR when 
clathrin is associated with lipid rafts (78).  
As shown in paper IV, inhibition of Syk prevents the increase in 
formation of CCPs, and we propose that the formation of a Syk-
clathrin complex and Shiga toxin-induced phosphorylation of 
CHC is important for clathrin recruitment. Syk has also been 
shown to associate with clathrin and mediate endocytosis of the 
human rhinovirus via a PI(3)-kinase-dependent pathway (154). 
There seems to be a correlation in time between the maximum 
increase in the number of CCPs that we observe in paper IV and 
the maximum increase in Syk-induced CHC-phosphorylation 
(84). Yet, the mechanism of such a link needs further 
clarification. Accordingly, the site of Shiga toxin-induced 
phosphorylation on CHC was recently identified (85). This site, 
Y1477, is also phosphorylated during ligand-induced endocytosis 
of EGF (74) and lies within a domain that has been suggested to 
be involved in clathrin assembly (155,156). Another possibility is 
that the role of phosphorylated CHC is to recruit adaptor proteins 
necessary for the formation of CCPs. 
Based on the fact that different cargo bind to different receptors 
and the discovery of several cargo-specialized adaptor proteins 
for clathrin-mediated endocytosis it has been suggested that 
cargo-specific subgroups of CCPs exist (19). 
Because the transferrin receptor (TfR) is endocytosed 
independently of ligand-binding, transferrin (Tf) is frequently 
used as a marker of clathrin-dependent endocytosis. However, in 
our study we did not observe any increase in the uptake of Tf 
upon Shiga toxin B-incubation, a result raising the question 
whether Shiga toxin and Tf may be taken up partly into different 
types of CCPs. To address this issue, clathrin-mediated 
endocytosis of Shiga toxin and Tf should be followed by TIRF 
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microscopy. Shiga toxin and Tf, although co-localizing in 
immunofluorescence, are enriched in different sub-domains on 
early/recycling endosomes as observed by EM (107). Different 
requirements for endocytosis may lead to sorting at an early stage 
and thus result in localization to different microdomains of early 
endosomes (107,157).  
The influenza virus has been shown to induce CCP formation at 
its binding sites, but whether the number of CCPs is increased in 
general is not clear (158). Epsin 1 has been identified as a cargo-
specific adaptor for the influenza virus, and clathrin-dependent 
endocytosis of this virus seems to occur independently of AP-2 at 
37ºC (159). It has been claimed that endocytosis of EGFR may 
proceed independently of AP-2 (160), but the use of ligand-
binding at 4ºC in such studies has been criticized, and a later 
study performed at 37ºC showed that AP-2 was essential for 
internalization of EGFR (161). Whether AP-2 is needed for Shiga 
toxin endocytosis is not known.  
How signaling can be induced through binding of Shiga toxin to 
its glycolipid receptor has not been clarified. Receptor cross-
linking by Shiga toxin may induce new interactions, and lead to 
binding of signaling proteins. A candidate protein may be the 
trans-membrane receptor Fas, whose extracellular domain 
interacts with Gb3, or other proteins sharing the same glycolipid-
binding motif (162). Two unidentified proteins have also been 
found to interact with Shiga toxin (163). Moreover, Syk can be 
activated by mechanisms that are independent of phosphorylation, 
as shown when Syk binds to the integrin 3 cytoplasmic tail 
(164,165). A signaling cascade involving other kinases may also 
be induced. 
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Sorting nexins and PI requirements in 
endosome-to-Golgi transport of toxins 
In papers II and III we used siRNA to demonstrate that the 
PI(3)P-binding sorting nexins SNX1, SNX2, and SNX4 mediate 
endosome-to-Golgi trafficking of toxins. By interfering with the 
activity of the PI3-kinase hVps34 we also showed that a pool of 
PI(3)P made by hVps34 is required for this transport.  
Proteins of the sorting nexin family share the phosphoinositide-
binding PX-domain and have been implicated in sorting or 
budding events in the endocytic pathway (26,166,167). The 
retromer was first identified in yeast where it transports the 
vacuolar hydrolase receptor Vps10p from pre-vacuolar endo-
somes to the Golgi in a Vps34-dependent manner (53,58,168). 
The yeast retromer consists of two subcomplexes, a Vps26p/ 
Vps29p/Vps35p trimer and a Vps5p/Vps17p dimer. SNX1 and 
SNX2 are both orthologs of yeast Vps5p, but during the course of 
our study, the role of SNX2 in the retromer was debated, as 
different studies gave conflicting results (152,153,169-173). 
Genetic studies in mice indicate that SNX2 is indeed a retromer 
component (172), and it has been shown that SNX1 and SNX2 
are essential but functionally redundant during embryonic 
development in mice (169,172) and in trafficking of the CI-MPR 
in HeLa cells (173). In paper III we concluded that SNX1 and 
SNX2 are both necessary for efficient endosome-to-Golgi traffic-
king of Shiga toxin. However, since knockdown of SNX1 or 
SNX2 alone also inhibits Shiga toxin transport, they are only 
partly redundant. The involvement of SNX1 in Shiga toxin trans-
port to the TGN was confirmed by the work of others (110), and 
the importance of the retromer component hVps26 in Shiga toxin 
trafficking has also been demonstrated by siRNA (111). Insuf-
ficient siRNA-mediated knockdown or cell type differences may 
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be the reason behind the discrepancy between different studies of 
SNX2 in transport to the TGN.  
SNX5 and SNX6 have been proposed as the mammalian ortho-
logs of yeast Vps17p. SiRNA against these two SNXs inhibited 
retrieval of the CI-MPR to the Golgi, giving a  phenotype similar 
to that of the known retromer components (59). Moreover, SNX6 
was shown to form a complex with SNX1, and SNX5/6 was also 
required for the association of SNX1 with endosomes (59).  
In paper II we reported that SNX2 and SNX4 mediate transport of 
ricin to the Golgi apparatus in a partly redundant manner, and we 
suggested that they act in parallel pathways. Furthermore, ricin 
transport seemed to proceed even in the absence of SNX1. With 
both SNX1 and SNX2 as parts of the retromer complex, such 
results may seem contradictory, but it is not unlikely that SNX2 
can mediate a retromer-independent pathway to the Golgi. SNX1 
and SNX2 may form homo-dimers as well as hetero-dimers with 
one another or with SNX5 and SNX6 (153). SNX1 has been 
shown to mediate retromer-independent sorting of PAR1 to lyso-
somes (174), and the other SNXs may have independent functions 
either alone or as part of other complexes. Consequently, we 
cannot exclude that SNX1 and SNX2 may act in parallel 
pathways when regulating transport of Shiga toxin to the TGN 
(paper III). 
A complex consisting of SNX4, SNX41 and SNX42 has been 
shown to mediate a transport pathway independent of the retro-
mer in yeast transporting cargo from an earlier endosomal 
compartment to the Golgi (60). The retrieval of CI-MPR, which 
requires functional retromer, was shown to proceed independently 
of SNX4 in HeLa cells (61). Thus, SNX4 and the retromer seem 
to function in parallel pathways also in mammalian cells, which is 
in agreement with our conclusion from paper II. 
SNX4 contains a curvature-sensing BAR domain and may form a 
coat complex similar to the retromer together with yet unidenti-
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fied proteins. Mammalian equivalents of SNX41 and SNX42 
have not been established, but based on phylogenetic analysis 
SNX7 and SNX30 are possible candidates (26). There is so far no 
evidence for the formation of a complex between SNX2 and 
SNX4.  
Although co-localizing to some extent on endosomes, SNX1 and 
SNX4 are found on separate tubular profiles arising from the 
same compartment (61). Different affinities for different PIs may 
target SNXs to separate membrane domains. SNX1 has similar 
affinities for PI(3)P and PI(3,5)P2 (57). It is not yet clear whether 
it is the direct binding of PI(3)P to SNX1 and SNX2 or rather 
binding of PI(3,5)P2 that is required for transport of toxins to the 
TGN. The PIKFyve kinase converts PI(3)P into PI(3,5)P2, and 
upon siRNA-mediated suppression of PIKFyve retrieval of CI-
MPR from endosomes to the Golgi is inhibited, whereas EGFR 
and TfR trafficking remain undisturbed (175). Thus, it has been 
suggested that SNX1 may work mainly in the PI(3,5)P2-depen-
dent pathway, whereas SNX4 has a role in endosome-to-TGN 
transport as well as transport between early endosomes and the 
early recycling compartment (61). 
PI(3)P is concentrated in Rab5-positive domains of early endo-
somes (49) and Rab5 has been shown to activate hVps34 (176). 
Thus, Rab5 may promote the hVps34-catalyzed production of 
PI(3)P required for recruiting SNXs to early endosomes that we 
report in paper II. A recent report suggests that Rab5 and Rab7 
recruit retromer components to the endosome in a sequential 
manner, with Rab5 recruiting the SNX dimer and GTP-bound 
Rab 7 binding directly to the hVps trimer (177). The authors 
provide evidence that overexpression of inactive Rab5 and siRNA 
against Rab7 perturb retrieval of CI-MPR to the Golgi (177). In 
contrast, a screen for RabGAPs inhibiting Shiga toxin trafficking 
showed that neither overexpression of mutant RabGAP5 nor 
siRNA against Rab5 was relevant for Shiga toxin transport to the 
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Golgi (118). Further studies are therefore needed to clarify the 
possible involvement of Rab5 and Rab7 in toxin transport.  
Recently identified regulators of retromer function include two 
proteins of the EHD family, which contain an Eps15 homology 
domain that interacts with PIs. EHD1 and EHD3 are required for 
proper localization of SNX1 and SNX2 to endosomal tubules.  
Moreover, EHD3 and its interaction partner, the Rab4/5 effector 
rabenosyn-5 have been shown to mediate trafficking of Shiga 
toxin as well as CI-MPR to the TGN (112,178). It would be 
interesting to know whether such retromer-regulating proteins or 
effectors are exclusive for this pathway or if they also play a role 
in the SNX4-mediated route to the TGN. 
Rab6A and Rab6A’ in retrograde 
transport of toxins 
Being localized to the Golgi apparatus (179), Rab6 has long been 
considered as a candidate for regulating transport to, from, or 
within this compartment. In paper I we demonstrated that the two 
Rab6 isoforms Rab6A and Rab6A’ are both involved in 
endosome-to-Golgi transport of ricin, and that they are partly 
redundant. Moreover, when Rab6A mRNA was reduced below a 
certain level, Rab6A’ was up-regulated and seemed to take over 
the function of Rab6A. Rab6A, in contrast, could not substitute 
for Rab6A’. This may indicate that Rab6A and Rab6A’ regulate 
parallel pathways. 
Compensatory transport mechanisms have also been described in 
other studies. In cells expressing mutant -COP, causing 
vesiculation of the Golgi apparatus, ricin was still capable of 
reaching the ER, most likely through the induction of an 
alternative pathway bypassing the Golgi (133).  
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Different strategies, such as overexpression of mutants (see 
Experimental considerations), inhibitory antibodies or studies of 
downstream effectors, have been used to elucidate the specific 
functions of the Rab6 splice variants, sometimes yielding con-
flicting results. When we initiated our study, overexpression of a 
dominant negative mutant of Rab6A’ had been shown to strongly 
inhibit endosome-to-TGN transport of Shiga toxin (113), and this 
finding was later strengthened by the use of siRNA (114). 
Overexpression of a GDP-restricted mutant of Rab6A did not 
inhibit the cytotoxic effect of ricin; however, this may be due to 
induction of an alternative pathway or the method used (180). 
Results obtained with overexpression of a GDP-restricted mutant 
of Rab6A had suggested a role in transport of Shiga toxin to the 
ER via a COPI-independent route (131,135). However, such a 
role for Rab6A was not confirmed by the later siRNA study 
(114). On the contrary, Rab6A’ proved to be the Rab6 isoform 
regulating this pathway, and a specific role for Rab6A in the 
transport of Shiga toxin was no longer assigned (114). Since 
Shiga toxin and ricin differ in their requirements for transport, it 
is not unlikely that Shiga toxin traffics to the Golgi independently 
of Rab6A. Our unpublished data nevertheless indicate that also 
Rab6A may play a role in Shiga toxin transport to the Golgi. 
Since Rab6A’ can be up-regulated upon depletion of Rab6A, such 
up-regulation may easily mask the effects of knocking down 
Rab6A, making these effects very difficult to measure. 
Variations in mechanisms of action between Rab6A and Rab6A’ 
may be explained by different requirements for effectors. Several 
Rab6-interacting proteins have been identified, but so far the only 
isoform-specific effector found is the motor protein Rabkinesin6, 
which only interacts with Rab6A and is involved in cytokinesis 
(45,181-183). Furthermore, dynein light chain interacts directly 
with both isoforms, but binds preferentially to GTP-bound Rab6A 
and GDP-bound Rab6A’ and Rab6B (184). Both Rab6A and 
Rab6A’ have been shown to interact with and regulate 
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recruitment of the dynactin complex to Golgi membranes  and 
thereby mediate microtubule-dependent recycling from Golgi to 
ER (185,186). Rab6A’ has also been shown to function in 
cytokinesis (187).  
An increasing number of components in the retrograde machinery 
have been identified, and new studies have shed more light on 
how these factors are integrated. Most likely the role of 
Rab6A/A’ is to bind effector proteins at the TGN and thereby 
promote fusion. Proper function of the COG complex, a putative 
tethering factor that promotes Shiga toxin transport to the TGN, 
has been reported to depend on active Rab6 (123,188). The COG 
complex seems to interact with the syntaxin5/Ykt6/GS28/GS15 
SNARE complex, which also has been found to play a role in 
trafficking of Shiga toxin (123,125). In addition, it has been 
described that Rab6 may regulate a pathway separate from the 
COG-dependent route involving the protein complex ZW10/ 
RINT-1 (188). It would be of interest to study if Rab6A and 
Rab6A’ might play different roles in these pathways. 
Rab6 has also been shown to mediate the localization of the coil-
coiled tethering protein GCC185 to the TGN in cooperation with 
Arl1; and GCC185 is again involved in Shiga toxin transport 
(122,189). TMF is yet another protein that modulates Rab6-
dependent trafficking of Shiga toxin from early endosomes to the 
TGN and Golgi-resident enzymes to the ER (116). 
Rab6 and Rab11 seem to regulate Shiga toxin transport in a 
sequential manner, possibly linked by Rab6-interacting protein 1 
(R6IP1) (113,190). In a screen for RabGAPs inhibiting trafficking 
of Shiga toxin to the Golgi, RN-tre and 5 other GAPs were 
identified, and the target of RN-tre, the Golgi-localized Rab43, 
was shown to regulate transport of Shiga toxin (118). 
Accordingly, not yet investigated Rabs may contribute to the 
transport of ricin and Shiga toxin to the TGN, either acting 
sequentially or in parallel pathways. 
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Protein trafficking disorders related to 
Rabs and SNXs 
Studies of disease may provide insight into compensatory 
mechanisms of the trafficking machinery and vice versa. Inherited 
mutations of Rab proteins and Rab-associated proteins seem to be 
associated with several disorders affecting the immune system 
and the neuronal system (191,192). 
Loss of function of the Rab27a isoform can be compensated by 
Rab27b; however, Rab27b is not expressed in the lysosome-
related organelles of melanocytes and cytotoxic T-cells (193). 
Mutations in Rab27a therefore specifically affect lysosomal 
transport in these cells, resulting in pigment dilution of the hair 
and uncontrolled T-lymphocyte activation, known as the Griscelli 
syndrome type II. Also mutations in Rab7,  Rab3GAPs and GDP 
dissociation inhibitor 1 (GDI1) are linked to such diseases (192),  
Mutations leading to disease have not yet been discovered for 
Rab6; however the Rab proteins may also play a more indirect 
role. It has been suggested that Rab6A/A’ and Rab1 target the 
protein OCRL1 (oculocerebrorenal syndrome of Lowe protein 1) 
to Golgi membranes in a partly redundant manner with Rab1 
being the most essential. The Rab proteins then  seem to stimulate  
the phosphatase activity of OCRL1 (194). OCRL1  is involved in 
endosome-to-Golgi trafficking, and mutations in this protein  
cause accumulation of PI(4,5)P2 resulting in the Lowe syndrome 
(108).  
Defects in the retrograde trafficking pathway are also associated 
with more common diseases such as Alzheimer and cancer.  
Rab6 is up-regulated in brain tissue from patients with Alzheimer 
disease, and the increase in Rab6 levels does not seem to be due 
to activation of the unfolded protein response (195). The authors 
propose a role for Rab6 in post-ER quality control and that there 
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is an increased demand for Golgi-ER-recycling because of accu-
mulation of proteins in the Golgi in Alzheimer disease brain. 
Defects in the retromer pathway from endosomes to the Golgi 
apparatus may also play a role in late-onset Alzheimer disease 
(196,197). Vps35 expression levels on microarray are reduced in 
Alzheimer disease brain (196), and SNX1 and Vps35 seem to be 
involved in the retrieval of the amyloid precursor protein (APP) -
binding receptor SorLa to the TGN (92). It has been proposed that 
when transport of APP from endosomes to the Golgi is delayed, 
there is an increase in the processing of APP into the amyloid- 
peptides which are accumulated in Alzheimer disease brain (197).  
Furthermore, down-regulation of SNX1 has been shown to play a 
role in development of colon cancer, probably due to increased 
signaling from endosomes (198).  
Experimental considerations 
siRNA 
Small interfering RNA (siRNA) has become a major tool for 
studying protein function. RNAi was first discovered as a post-
transcriptional regulatory mechanism in Caenorhabditis elegans 
(199), and it was later shown that 21 nucleotide RNA oligos 
delivered to mammalian cells could silence the protein of interest 
(200). However, there are several non-specific effects to consider. 
Lipid-based transfection reagents have been shown to alter the 
gene expression profile as opposed to using electroporation for 
siRNA delivery (201). Delivering siRNA to cells also triggers the 
interferon response and thereby activates the Jak-Stat signaling 
pathway (202). Yet, the greatest concern is the non-target effects 
arising from sequence similarities between the mRNA of interest 
and other mRNAs. Similarities in as few as 5 base-pairs in the 3’ 
UTR-region may cause unwanted silencing of off-target mRNA, 
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an effect which is difficult to predict (203). It is therefore essen-
tial to use several siRNA oligos against a target protein to 
minimize the risk of false conclusions.  
In our studies we used both vector-based and oligo-based siRNA. 
Vector-based siRNA is less suitable in cells where the 
transfection efficiency is low, and it is also difficult to modulate 
knockdown. It may be of advantage for proteins with very long 
half-lives, since re-transfection is not required; however we 
observed an efficient knockdown at the protein level from 48-96 
hours after transfection in all our experiments.  
Another pitfall may be the long-term nature of the siRNA 
experiments, which may allow for induction of compensatory 
mechanisms and transport pathways not operating under normal 
conditions. In the case of Rab6A/A’ the time-course may be of 
importance for up-regulation of the other isoform. 
Overexpression 
Transient overexpression of mutant proteins was used in paper II 
to study the role of hVps34 in transport of ricin, and the data 
obtained were in agreement with the effects found by siRNA. The 
use of active or dominant negative mutants of Rab6A and Rab6A’ 
seems to yield some conflicting data compared to results obtained 
by siRNA. Overexpression of for instance the Rab6A isoform 
may sequester effector proteins that are common for both 
isoforms. As a consequence, an observed phenotype may not be 
the result of activating Rab6A, but rather of inhibiting Rab6A’, 
and the use of mutants should therefore be combined with other 
methods. 
Early studies using overexpression of wildtype and mutant SNX1 
and mutant SNX2 indicated a role for these proteins in the 
transport of EGFR to lysosomes for degradation (170,204,205). 
In contrast, siRNAs against SNX1 and SNX2 had no effect on 
lysosomal trafficking of EGFR (57,170). It was suggested that 
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SNX1 overexpression induces tubules on early endosomes pro-
moting lysosomal transport in general (57). Thus, overexpression 
does not seem to be suitable for studies of SNX function.  
In paper IV we relied on HeLa cells stably expressing the 2-
subunit of the clathrin adaptor complex AP-2 fused to EGFP. In 
BSCI cells (monkey kidney epithelial cells) this fusion protein 
was shown to co-localize with endogenous AP-2 and transiently 
expressed clathrin light chain and did not prevent the uptake of Tf 
(206). 
Microscopy 
Studies of clathrin-mediated endocytosis have benefited from 
advances in live-cell imaging. The use of spinning disk confocal 
microscopy as in paper IV allows more rapid image collection 
and less photobleaching than TIRF (total internal reflection 
fluorescence) and ordinary confocal; however, some out-of-focus 
light is collected. The problem may be reduced by installing a 
motorized spherical aberration correction (SAC) -unit, which 
corrects for the differences in refractive index between the lens, 
oil, coverslip, media and specimen. This set-up made imaging of 
internalizing CCPs in the same cell area possible for up to 15 
minutes. A drawback is that the cell surface attached to the 
coverslip, the only surface suitable for imaging, in HeLa cells 
displays a number of static clathrin structures in addition to 
internalizing CCPs. It is not known whether such plaques have a 
biological significance or are artifacts of cell plating. 
Measurements of endosome-to-Golgi transport. 
For measuring transport of ricin and Shiga toxin to the TGN we 
took advantage of modified toxins containing sulfation sites 
(130,207).  Sulfation is a TGN-specific modification of newly 
synthesized proteins, and by supplementing media with 
radioactive sulfate the amount of sulfated toxin reaching the TGN 
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can be measured by autoradiography. The total amount of 
sulfated proteins should also be taken into account to make sure 
that the effects observed are not due to alterations in the sulfation 
machinery, protein synthesis or experimental conditions. This is 
done by counting the radioactivity in TCA-precipitates from the 
samples. 
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Conclusions and 
perspectives 
In paper IV we show that Shiga toxin increases the formation of 
CCPs at the plasma membrane, most likely via signaling through 
the Syk kinase. Shiga toxin as well as viruses and receptor 
tyrosine kinases have been shown to induce their own uptake 
through clathrin coated pits by kinase-dependent phosphorylation 
of clathrin heavy chain. Yet, further details about the mechanism 
behind the increase in CCPs as well as the first steps of Shiga 
toxin-induced signaling remain to be studied. 
While over the last decades endocytic pathways and lysosomal 
trafficking have been thoroughly studied, the components of the 
retrograde pathway from early endosomes to the Golgi apparatus 
have gained less attention. In papers I, II, and III we have studied 
proteins that proved to be functionally redundant in toxin 
trafficking between endosomes and the TGN, either acting as 
parts of a complex, being interchangeable in the same pathway, or 
operating in parallel pathways. We showed that SNX1 and SNX2 
are involved in transport of Shiga toxin from endosomes to the 
Golgi and that they are partly redundant. Furthermore, we provide 
evidence that ricin depends on parallel trafficking pathways 
regulated by SNX2 and SNX4 on its way to the TGN. HVps34 
seems to catalyze the formation of PIs important for all these 
transport pathways. In addition, we established a role for the two 
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Rab6 isoforms Rab6A and Rab6A’ in endosome-to-Golgi-
transport of ricin. 
To fully elucidate how the increasing number of identified comp-
onents in endosome-to-Golgi trafficking are connected, further 
studies will be necessary. Rab6A and Rab6A’ may regulate 
parallel pathways to the TGN or be partly interchangeable in the 
same pathway. We assume that these Rabs are important for 
docking transport vesicles to the TGN membrane, but we do not 
know whether they interact with one or both SNARE complexes 
involved in Shiga toxin transport, or whether they operate in the 
same pathway as SNX1, SNX2 or SNX4.  
Mutations in the genes encoding for the most essential proteins of 
the trafficking machinery will cause death of the organism before 
birth. In contrast, functionally redundant proteins and 
compensatory mechanisms render the cell less susceptible to 
defects in one protein or transport pathway; however, the defects 
may still cause illness. Thus, we may expect that future studies of 
compensatory mechanisms in intracellular trafficking will 
contribute to increased understanding of disease. 
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